Harbour BioMed

Harbour BioMed is a publicly traded biotech (HKEX: 02142) with a mission to deliver breakthrough medicines through its innovative antibody technology platforms. The company has successfully transitioned from a technology licensor to a clinical-stage entity with a maturing pipeline, evidenced by multiple out-licensing deals and strategic collaborations with major pharmaceutical companies. Its 'global for global' strategy leverages R&D centers in the US, Europe, and China to build a diversified portfolio of novel therapeutics.

Proprietary Harbour Mice® platform generates fully human monoclonal antibodies, including heavy-chain-only (HCAb) formats, which serve as building blocks for next-generation bispecifics, multi-specifics, ADCs, and LYTACs, augmented by an integrated AI discovery engine.

Harbour BioMed competes with large pharma and biotech in therapeutic development and with other platform technology companies like Regeneron, AbCellera, and OmniAb. Its differentiation lies in the unique HCAb format enabling simplified engineering of complex molecules and its integrated global partnership model.